Medical disclaimer: This article is for educational purposes only and is not medical advice. BPC-157 is not FDA-approved for any use. Human research is extremely limited. Consult a licensed physician before considering any peptide. Never source peptides from unregulated online vendors.
BPC-157 is the most talked-about peptide on the internet — and the most misunderstood. Depending on who you ask, it’s either a miracle healing compound or an unproven research chemical with real safety questions. The truth, as usual, is more complicated. This article walks through what three decades of research actually shows, where the evidence stops, and what regulators and physicians want you to know.
For context on how BPC-157 fits into the broader peptide landscape, see our peptide dosage chart reference guide and our complete peptide guide for beginners.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic peptide made up of 15 amino acids. It was originally derived from a protein found in human gastric juice, which is why early research focused heavily on gut healing.
The Animal Research: Genuinely Impressive
Over 100 published animal studies spanning three decades have reported effects including:
- Tendon and ligament healing: Rat studies show accelerated healing of Achilles tendon transections and medial collateral ligament injuries
- Muscle repair: Improved healing of crushed and transected muscle tissue in rodent models
- Gut protection: Healing of gastric ulcers, inflammatory bowel lesions, and intestinal anastomoses
- Nerve regeneration: Improved outcomes in models of sciatic nerve injury and traumatic brain injury
- Bone healing: Enhanced fracture repair in rabbit models
- Vascular effects: Promotion of angiogenesis and endothelial protection
- Neuroprotection: Counteraction of symptoms resembling Parkinson’s, Alzheimer’s, and schizophrenia in animal models
A 2025 systematic review in the American Journal of Sports Medicine screened 544 articles on BPC-157 for orthopaedic applications. Of the 36 studies that met inclusion criteria, 35 were preclinical animal models.
The Human Research: Three Small Studies
- Interstitial cystitis pilot (2024): 12 patients received BPC-157 bladder injections. 80-100% symptom resolution reported. No placebo control, tiny sample.
- Knee pain pilot (2021): 16 patients with knee pain. 87.5% reported significant relief at 6-12 months. No placebo control.
- IV safety study (2025): 2 adults received up to 20 mg IV BPC-157 with no adverse effects observed.
Total human subjects across all published trials: fewer than 30. No randomized controlled trials exist.
What the FDA Says
- 2023: The FDA placed BPC-157 on the Category 2 bulk drug substances list, blocking compounding pharmacies from preparing it, citing insufficient safety data.
- July 2026 FDA advisory meeting: FDA scientists presented adverse-event reports and flagged a 2020 study showing signs of liver toxicity in rats and dogs injected with BPC-157.
- Adverse events: The FDA’s adverse-event database includes a report of a 36-year-old woman hospitalized after taking BPC-157 for weight control and a skin disorder, and a 48-year-old man hospitalized with a “life-threatening” condition.
WADA and Sports
BPC-157 has been prohibited by the World Anti-Doping Agency since 2022 under category S0 (Unapproved Substances), banned at all times for competitive athletes.
The Bottom Line
BPC-157 sits in an unusual position: one of the most-researched peptides in animals, and one of the least-researched in humans. The animal data is genuinely interesting. The human data is essentially three pilot studies totaling fewer than 30 people. The FDA has safety concerns, not reassurances.
This article is educational content, not medical advice. If you’re considering peptide therapy, start with our guide on how to find a doctor who prescribes peptides and have an evidence-based conversation with a licensed physician.
Frequently Asked Questions
Is BPC-157 FDA-approved? No. It is not approved for any indication. Its 2023 Category 2 listing blocked compounding.
Does BPC-157 actually work? We don’t know for humans. The animal data is unusually consistent, but the three small human pilots are encouraging anecdotes, not evidence.
What is the difference between BPC-157 and TB-500? Different mechanisms and research emphases; both unapproved and WADA-banned. See our TB-500 guide.
Interested in Peptides?
If you’re interested in exploring peptide therapy, click here to learn more.
